Breaking News Instant updates and real-time market news.

LGND

Ligand

$222.00

1.58 (0.72%)

10:59
07/13/18
07/13
10:59
07/13/18
10:59

Lemelson CIO calls on Congress to probe SEC failure to prosecute Ligand

Rev. Fr. Emmanuel Lemelson, the CIO of Lemelson Capital Management, LLC, a U.S.-based global Investment management firm, released a letter he has provided members of The U.S. House Committee on Oversight and Government Reform, U.S. House of Representatives Financial Services Committee, The U.S. Senate Committee on Banking, Housing, & Urban Affairs, The U.S. Senate Special Committee on Aging and the SEC Office of the Inspector General, outlining extensive alleged accounting, and securities fraud and abuse of federal and state healthcare laws by Ligand Pharmaceuticals, a U.S.-based publicly-traded pharmaceutical company. In the letter, Lemelson urged the Committees in both the House and the Senate to commence an investigation into these alleged abuses, as well as the Securities and Exchange Commissions "failure to stop them despite being provided abundant evidence of the alleged fraud spanning multiple years - failures he likens to the Commission's botched Enron and Madoff investigations that allowed these frauds to cost investors and the American taxpayers dearly." "We believe the greatest risk investors in Ligand face is the company may be excluded from government healthcare programs, found in violation of government regulations and face civil and criminal penalties that could result in imprisonment," Lemelson said. "It is inexplicable why the SEC has failed to act, given all of the disturbing developments that have been charted. Protecting the American investor and taxpayer, not to mention the sick who need reliable, affordable access to lifesaving medications must be a priority over fostering cozy relationships with Wall Street," Lemelson said.

  • 06

    Aug

LGND Ligand
$222.00

1.58 (0.72%)

04/19/18
HCWC
04/19/18
NO CHANGE
Target $182
HCWC
Buy
H.C. Wainwright reiterates Buy on Ligand after Novartis reports Q1
H.C. Wainwright analyst Joseph Pantginis says the Promacta franchise remains strong after Ligand Pharmaceuticals (LGND) partner Novartis (NVS) reported Q1 sales Promacta revenue of $257M. The analyst projects 2018 is the year that Promacta officially reaches blockbuster status, or $1B in sales. Further, he points out that Retrophin (RTRX), another Ligand partner, earlier this month announced that the first patient has been enrolled into the Phase 3 Duplex study using sparsentan to treat patients with focal segmental glomerulosclerosis. Pantginis is encouraged by the start of the Phase 3 saying it has the potential to lock in a fixed 9% royalty to Ligand, if approved. He currently project peak sales of $825M but feels the drug could reach blockbuster status based on its first-to-market status. Pantginis keeps a Buy rating on Ligand Pharmaceuticals with a $182 price target.
06/21/18
ARGS
06/21/18
INITIATION
Target $260
ARGS
Buy
Ligand initiated with a Buy at Argus
Argus analyst Mike Jaffe initiated Ligand Pharmaceuticals with a Buy rating and a price target of $260, saying the company is on track to generate solid earnings growth over the next several years thanks to its primary products - Promacta with use in blood clotting and Kyprolis for treatment of multiple myeloma. Jaffe adds that the company also has a "strong pipeline", with over half of its 165 programs under license currently in the clinical development or later stage. The analyst is also positive on Ligand's valuation at a PEG ratio of 1.2-times, which is "well below" the peer biotech industry average of 1.8-times.
06/27/18
CHLM
06/27/18
NO CHANGE
Target $230
CHLM
Buy
Ligand price target raised to $230 from $200 at Craig-Hallum
Craig-Hallum analyst Matt Hewitt raised his price target for Ligand to $230 from $200 following the company's announcement that WuXi Biologics has amended its license agreement for the OmniAb platform and has made a cash payment of $47M to Ligand. The analyst continues to believe that Ligand is a unique asset geared to provide investors with excellent earnings growth over the next several years as it layers in additional commercial assets from its extensive partnered pipeline. He reiterates a Buy rating on the shares.
06/28/18
HCWC
06/28/18
NO CHANGE
Target $239
HCWC
Buy
Ligand price target raised to $239 from $182 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target for Ligand Pharmaceuticals to $239 after the company amended its OmniAb agreement with WuXi Biologics and received a $47M payment. With its "coffers overflowing" with cash, the analyst expects Ligand's "strategic shopping should ramp up even more." Further, the company could also be highly selective in bringing additional internal pipeline assets forward, such as CE-Iohexol, expected to enter the clinic late 2018, Pantginis tells investors in a research note. He maintains a Buy rating on Ligand.

TODAY'S FREE FLY STORIES

VLO

Valero

$103.31

-0.36 (-0.35%)

, VLP

Valero Energy Partners

$39.94

0.5 (1.27%)

16:29
10/18/18
10/18
16:29
10/18/18
16:29
Hot Stocks
Valero to acquire Valero Energy Partners for $42.25 per common unit in cash »

Valero Energy Corporation…

VLO

Valero

$103.31

-0.36 (-0.35%)

VLP

Valero Energy Partners

$39.94

0.5 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 25

    Oct

INAP

Internap

$11.00

-0.8 (-6.78%)

16:28
10/18/18
10/18
16:28
10/18/18
16:28
Syndicate
Internap files to sell common stock, no amount given »

Jefferies and Credit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 15

    Nov

CBRL

Cracker Barrel

$155.12

-2.31 (-1.47%)

16:28
10/18/18
10/18
16:28
10/18/18
16:28
Initiation
Cracker Barrel initiated  »

Cracker Barrel initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTRA

Natera

$21.40

0.09 (0.42%)

, NTGN

Neon Therapeutics

$8.32

0.31 (3.87%)

16:27
10/18/18
10/18
16:27
10/18/18
16:27
Hot Stocks
Natera, Neon Therapeutics announce clinical trial collaboration for NEO-PV-01 »

Natera (NTRA) and Neon…

NTRA

Natera

$21.40

0.09 (0.42%)

NTGN

Neon Therapeutics

$8.32

0.31 (3.87%)

MRK

Merck

$72.22

0.42 (0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 22

    Oct

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 07

    Nov

  • 27

    Nov

  • 11

    Jan

  • 16

    Feb

CBS

CBS

$56.17

0.3 (0.54%)

16:27
10/18/18
10/18
16:27
10/18/18
16:27
Hot Stocks
CBS names David Nevins as Chief Creative Officer »

David Nevins has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

SFIX

Stitch Fix

$25.65

0.34 (1.34%)

, WMT

Walmart

$96.19

-0.37 (-0.38%)

16:27
10/18/18
10/18
16:27
10/18/18
16:27
Hot Stocks
Stitch Fix promotes Mike Smith to COO and President »

On October 16, the Board…

SFIX

Stitch Fix

$25.65

0.34 (1.34%)

WMT

Walmart

$96.19

-0.37 (-0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 13

    Nov

  • 15

    Nov

CBS

CBS

$56.17

0.3 (0.54%)

16:27
10/18/18
10/18
16:27
10/18/18
16:27
Hot Stocks
CBS names Christina Spade CFO »

Christina Spade has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

CMG

Chipotle

$431.72

2.09 (0.49%)

16:26
10/18/18
10/18
16:26
10/18/18
16:26
Initiation
Chipotle initiated  »

Chipotle initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTRA

Natera

$21.40

0.09 (0.42%)

, NTGN

Neon Therapeutics

$8.32

0.31 (3.87%)

16:25
10/18/18
10/18
16:25
10/18/18
16:25
Hot Stocks
Natera and Neon Therapeutics collaborate on cancer vaccine trial »

Natera (NTRA) and Neon…

NTRA

Natera

$21.40

0.09 (0.42%)

NTGN

Neon Therapeutics

$8.32

0.31 (3.87%)

MRK

Merck

$72.22

0.42 (0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 22

    Oct

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 07

    Nov

  • 27

    Nov

  • 11

    Jan

  • 16

    Feb

CTXS

Citrix

$103.40

-1.73 (-1.65%)

16:24
10/18/18
10/18
16:24
10/18/18
16:24
Initiation
Citrix initiated  »

Citrix initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

DOCU

DocuSign

$46.26

-1.305 (-2.74%)

16:24
10/18/18
10/18
16:24
10/18/18
16:24
Initiation
DocuSign initiated  »

DocuSign initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

MSFT

Microsoft

$108.54

-2.18 (-1.97%)

16:24
10/18/18
10/18
16:24
10/18/18
16:24
Initiation
Microsoft initiated  »

Microsoft initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 28

    Oct

  • 13

    Nov

  • 28

    Nov

  • 03

    Mar

CAKE

Cheesecake Factory

$50.32

-0.79 (-1.55%)

16:23
10/18/18
10/18
16:23
10/18/18
16:23
Initiation
Cheesecake Factory initiated  »

Cheesecake Factory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 05

    Nov

  • 14

    Nov

MYL

Mylan

$32.42

-0.61 (-1.85%)

, PFE

Pfizer

$44.02

-0.55 (-1.23%)

16:23
10/18/18
10/18
16:23
10/18/18
16:23
Hot Stocks
Mylan announces U.S. launch of generic Depo-Provera »

Mylan (MYL) announced the…

MYL

Mylan

$32.42

-0.61 (-1.85%)

PFE

Pfizer

$44.02

-0.55 (-1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 22

    Oct

  • 30

    Oct

  • 05

    Nov

  • 07

    Nov

  • 13

    Nov

PYPL

PayPal

$77.50

-2.61 (-3.26%)

16:23
10/18/18
10/18
16:23
10/18/18
16:23
Hot Stocks
PayPal reports Venmo processed about $17B of TPV in Q3 »

PayPal said: "Strong…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 22

    Oct

  • 13

    Nov

  • 13

    Nov

  • 26

    Nov

CLDR

Cloudera

16:23
10/18/18
10/18
16:23
10/18/18
16:23
Initiation
Cloudera initiated  »

Cloudera initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

PANW

Palo Alto Networks

$202.61

-3.375 (-1.64%)

16:22
10/18/18
10/18
16:22
10/18/18
16:22
Initiation
Palo Alto Networks initiated  »

Palo Alto Networks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

VRNS

Varonis

$64.72

-0.935 (-1.42%)

16:22
10/18/18
10/18
16:22
10/18/18
16:22
Initiation
Varonis initiated  »

Varonis initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 01

    Nov

  • 13

    Nov

CHKP

Check Point

$110.75

-1.34 (-1.20%)

16:22
10/18/18
10/18
16:22
10/18/18
16:22
Initiation
Check Point initiated  »

Check Point initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 10

    Dec

JCOM

j2 Global

$73.78

-1.64 (-2.17%)

16:22
10/18/18
10/18
16:22
10/18/18
16:22
Initiation
j2 Global initiated  »

j2 Global initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

FFBC

First Financial Bancorp

$27.42

-0.76 (-2.70%)

16:21
10/18/18
10/18
16:21
10/18/18
16:21
Earnings
First Financial Bancorp reports Q3 EPS 51c with items, consensus 57c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 31

    Oct

MCD

McDonald's

$166.84

0.06 (0.04%)

16:21
10/18/18
10/18
16:21
10/18/18
16:21
Initiation
McDonald's initiated  »

McDonald's initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

VRNT

Verint

$45.76

-0.91 (-1.95%)

16:21
10/18/18
10/18
16:21
10/18/18
16:21
Initiation
Verint initiated  »

Verint initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSI

Vitamin Shoppe

$9.54

-0.55 (-5.45%)

16:21
10/18/18
10/18
16:21
10/18/18
16:21
Hot Stocks
Vitamin Shoppe names Stacey Renfro Chief Customer & Digital Experience Officer »

Vitamin Shoppe announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EAT

Brinker

$47.64

-0.72 (-1.49%)

16:21
10/18/18
10/18
16:21
10/18/18
16:21
Initiation
Brinker initiated  »

Brinker initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.